Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
Conditions: Advanced HER2 Negative Breast Carcinoma; HRD+Breast Cancer Interventions: Drug: fluzoparib+chidamide; Drug: fluzoparib+camrelizumab Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Hospitals | Research